Navigation Links
Other highlights in the Feb. 26 JNCI
Date:2/26/2008

No Additional Benefit Found for Personalized Intervention to Promote Regular Mammography Screening

Two different interventions did not significantly increase regular mammography screening in a large randomized study.

Behavioral interventions, such as personalized mailings, have been reported to increase one-time cancer screening. However, few studies have examined the impact of behavioral interventions on regular or on-going participation in screening exams.

Sally Vernon, Ph.D., of the University of Texas School of Public Health in Houston and colleagues assigned 5,500 female veterans to one of three interventions designed to encourage annual mammograms - a baseline survey plus a targeted mailing, a baseline survey plus a targeted mailing that was tailored to individual participants, or the baseline survey alone. The investigators then looked to see how many women in each group had completed two mammograms as recommended during the three-year follow-up period.

Neither the targeted mailing nor the targeted and tailored mailing was associated with a statistically significant increase in the percentage of women who had regular mammograms compared to the survey-only group.

Noting that two other trials have recently reported similar findings, the authors write, Collectively, these findings and ours provide little support for an additional benefit of using tailored interventions, either mailed or by telephone, to increase regular mammography screening.

In an accompanying paper by Deborah del Junco, Ph.D., of the University of Texas Health Science Center in Houston and colleagues, the researchers report that the results of the intervention trial are likely to be internally valid and applicable to the larger population. They assessed the validity of the trial by including two additional control groups in the study design and by comparing the characteristics of study participants with those of nonparticipants. The investigators found that the baseline survey by itself did not influence subsequent mammography screening rates. In addition, they found that mammography rates actually decreased in the final study year in the veteran population.

Similar rates of mammography coverage and compliance in the US female population and the decline reported for the US female population between 2000 and 2005 lend additional support to the generalizability of our results, the authors write.

Contact:
Article #1: Sally Vernon, Sally.W.Vernon@uth.tmc.edu, (713) 500-9760
Article #2: Deborah J. del Junco, Deborah.J.DelJunco@uth.tmc.edu, (713) 500-7902


Viral DNA Testing Is Cost-Effective for Cervical Cancer Screening

Adjustment of cervical cancer screening protocols as a woman ages may be cost-effective, regardless of whether she has been vaccinated against the human papillomavirus (HPV) that causes cervical cancer.

Since the release of cervical cancer screening guidelines in 2001 and 2003, more data has become available showing that HPV DNA-based testing is more effective in detecting precancerous changes in a womans cervix than standard cytology (Pap) tests. With these data and the development of a vaccine that prevents two types of HPV infection, analyses are needed that estimate both the effectiveness and cost of different screening strategies for U.S. women.

Using information about the frequency with which girls of different ages become infected with HPV and the likelihood that a persistent infection will lead to cancer, Sue J. Goldie, M.D., of Harvard School of Public Health in Boston and colleagues mathematically modeled the impact of each available screening technique in vaccinated and unvaccinated women. While a number of acceptable strategies were identified, the researchers found that the most cost-effective screening protocols for both vaccinated and unvaccinated women included cytology during the early part of a womans life, followed by HPV DNA-based screening after age 30. This strategy differs from most commonly used screening practices.

The investigators emphasized that the frequency of screening could be reduced in vaccinated individuals and the switch to DNA-based screening delayed by five years, relative to unvaccinated women. The researchers estimated that cervical cancer risk could be reduced by an additional 30 percent in future generations of American women provided there is high vaccine coverage in preadolescent girls, continued screening in vaccinated and unvaccinated women, and targeted efforts to recruit and screen women with historically poor access to cervical cancer prevention.

Our findings indicate that it may be worthwhile to consider strategies that differ according to age and vaccination status and to revisit screening options recommended for older women, the authors write.

In an accompanying editorial, Nancy Kiviat, M.D., of Harborview Medical Center in Seattle, and colleagues write The analyses presented [here] will undoubtedly support the urgently needed development of screening recommendations for the immediate future.

Contact:
Article: Robin Herman, rherman@hsph.harvard.edu, (617) 432-4388 or Todd Datz, tdatz@hsph.harvard.edu, (617) 432-3952
Editorial: Nancy Kiviat, nbk@u.washington.edu, (206) 731-3145


Interleukin Plays a Role in Ovarian Cancer Growth

Patients whose tumors produced high levels of interleukin-8 (IL-8) protein had a worse outcome than those with less IL-8. Blocking expression of IL-8 in mouse models of ovarian cancer slowed tumor growth by reducing blood vessel growth.

IL-8 expression is elevated in many human tumors. Previous work indicated that the protein stimulates tumor growth, blood vessel development, and metastasis in animal models. Suppressing its activity with antibody therapy slowed tumor growth in those models.

In the current study, Anil Sood, M.D., of the University of Texas M. D. Anderson Cancer Center in Houston and colleagues tested 102 human ovarian cancer tumor samples for IL-8 expression. Of those, 43 (42 percent) had high levels of the protein and 69 (58 percent) had low or no IL-8 expression. The researchers found that the women whose tumors had higher levels of IL-8 were more likely to have advanced disease and poorer survival.

When the team used small-interfering RNAs to block IL-8 gene expression in animal models of ovarian cancer, they saw that tumor growth was substantially reduced. The slowed growth appeared to be due to less blood vessel development.

Our findings suggest that IL-8 may be a potential therapeutic target in ovarian cancer, the authors write.

Contact: Scott Merville, sdmervil@mdanderson.org, (713) 792-0661


Also in February 26 JNCI:
http://www.eurekalert.org/emb_releases/2008-02/jotn-sn022108.php
http://www.eurekalert.org/emb_releases/2008-02/jotn-cp022108.php


'/>"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products
2. Autisms origins: Mothers antibody production may affect fetal brain
3. Drugs, Doctors and Death: Heath Ledger Becomes Another Victim
4. Breakfast BREAKS and Teen Music Phenomenon the Jonas Brothers Team Up to Raise Awareness about the Importance of Eating Breakfast
5. Another way to grow blood vessels
6. Study identifies another strategy for normalizing tumor blood supply
7. Hormone refractory prostate cancers more likely to spread to other organs
8. Varian Medical Systems Announces Symposia on RapidArc Technology for Faster, More Precise Radiotherapy Treatments
9. Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too
10. Enzyme structure reveals new drug targets for cancer and other diseases
11. Other highlights in the Feb. 12 JNCI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head Over ... on February 12th. Ms. Esparza qualified into this prestigious status after winning ... in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in the ...
(Date:2/23/2017)... CO (PRWEB) , ... February 23, 2017 , ... The ... announce the winner of the 2016 National Education Policy Center Bunkum Award. We invite ... reviewed in 2016. , This year’s Bunkum winner is the Center for American Progress ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, ... June: From Not to Hot,” which will begin airing on February 24, 2017. The ... millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Research and Markets ... Analysis & Trends - Industry Forecast to 2025" report to ... ... CAGR of around 23.8% over the next decade to reach approximately ... market estimates and forecasts for all the given segments on global ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... offering. ... Hemophilia Drugs Price Analysis and Strategies - 2016, provides drug pricing data ... following questions: What are the key drugs ... the Global Hemophilia market? What are the unit prices ...
(Date:2/24/2017)... -- In conjunction with DURECT Corporation,s (Nasdaq: DRRX ... are invited to listen to a conference call that ... March 14, 2017 at 4:30 pm Eastern Time (1:30 ... of the presentation will be available by accessing DURECT,s ... If you are unable to participate during the live ...
Breaking Medicine Technology: